| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile |
| 13 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile |
| 16 Jul 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
This Separation Agreement (this “Agreement”) is entered into by and between Glenn Reicin (“Executive”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together the “Company”), effective as of July 16, 202... |
| 14 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 50,381,309 shares of the Company’s common stock were represented in person or by proxy, c... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES |
| 14 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Separation Agreement (this “Agreement”) is entered into by and between Sandip Kapadia (“Executive”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together the “Company”), effective as of April 13, ... |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), effective as of April 2, 2026 (the “Effective Date”), is made by and between Harmony Biosciences Management, Inc., a Delaware corporation (the “Company”), and Peter Anastasiou (the “... |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG- TERM VALUE CREATION |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) |
| 23 Oct 2025 |
8-K: Results of Operations and Financial Condition
PLYMOUTH MEETING, Pa., October 23, 2025 /Business Wire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: |
| 24 Sep 2025 |
8-K: Regulation FD Disclosure
PLYMOUTH MEETING, Pa., September 24, 2025 -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). T... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HARMONY BIOSCIENCES REPORTS STRONG Q2 2025 FINANCIAL RESULTS AND REAFFIRMS 2025 REVENUE GUIDANCE; ON TRACK TO ANNOUNCE FRAGILE X TOPLINE DATA FROM PHASE 3 REGISTRATIONAL TRIAL IN Q3 2025 |
| 11 Jun 2025 |
8-K: Regulation FD Disclosure
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 |
| 05 Jun 2025 |
8-K: Other Events
PLYMOUTH MEETING, Pa., June 5, 2025 /Business Wire/ — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviat... |
| 15 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 15, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 45,446,787 shares of the Company’s common stock were represented in person or by proxy, c... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HARMONY BIOSCIENCES REPORTS STRONG Q1 2025 FINANCIAL RESULTS, HIGHLIGHTS ADVANCEMENT OF ITS PIPELINE AND UPCOMING CATALYSTS, AND REAFFIRMS 2025 REVENUE GUIDANCE |
| 03 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
PLYMOUTH MEETING, Pa., Apr. 3, 2025 -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. |
| 24 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
This Separation Agreement (this “Agreement”) is entered into by and between Jeffrey Dierks (“Executive”) and Harmony Biosciences Holdings, Inc., Harmony Biosciences, LLC and Harmony Biosciences Management, Inc. (together the “Company”), ... |
Loading...